{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:06:02Z","timestamp":1793066762687,"version":"4.5.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2024YFA1210200"],"award-info":[{"award-number":["2024YFA1210200"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204282"],"award-info":[{"award-number":["82204282"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ24H300006"],"award-info":[{"award-number":["LQ24H300006"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chinese Academy of Sciences President's International Fellowship Initiative","award":["2024VBB0004"],"award-info":[{"award-number":["2024VBB0004"]}]},{"name":"Future Network from International Partnership Program of Chinese Academy of Sciences","award":["083GJHZ2023012FN"],"award-info":[{"award-number":["083GJHZ2023012FN"]}]},{"name":"Grand Challenges from International Partnership Program of Chinese Academy of Sciences","award":["083GJHZ2023021GC"],"award-info":[{"award-number":["083GJHZ2023021GC"]}]},{"name":"High-level Innovative Research Institute from Department of Science and Technology of Guangdong Province","award":["2021B0909050003"],"award-info":[{"award-number":["2021B0909050003"]}]},{"name":"High-level Innovative Research Institute from Zhongshan Municipal Bureau of Science and Technology","award":["LJ2021001 & CXTD2022011"],"award-info":[{"award-number":["LJ2021001 & CXTD2022011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13346-025-01943-4","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T12:21:24Z","timestamp":1754914884000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nanotechnology-based shikonin delivery strategies for modulating the tumor immune microenvironment efficacy"],"prefix":"10.1007","volume":"16","author":[{"given":"Dipika Ramdas","family":"Kalambhe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akmal M.","family":"Asrorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurkhodja","family":"Mukhammedov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7300-1571","authenticated-orcid":false,"given":"Pengfei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"1943_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1943_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.cell.2017.08.012","volume":"170","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Cancer evolution constrained by the immune microenvironment. Cell. 2017;170:825\u20137.","journal-title":"Cell"},{"key":"1943_CR3","doi-asserted-by":"publisher","first-page":"100645","DOI":"10.1016\/j.drup.2019.100645","volume":"46","author":"YG Assaraf","year":"2019","unstructured":"Assaraf YG, Brozovic A, Goncalves AC, Jurkovicova D, Line A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR, Vasconcelos MH. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat. 2019;46:100645.","journal-title":"Drug Resist Updat"},{"key":"1943_CR4","first-page":"203","volume":"75","author":"LL Tang","year":"2025","unstructured":"Tang LL, Chen L, Xu GQ, Zhang N, Huang CL, Li WF, Mao YP, Zhou GQ, Lei F, Chen LS, Huang SH, Chen L, Chen YP, Zhang Y, Liu X, Xu C, Zhao Y, Li JB, Liu N, Xie FY, Guo R, Sun Y, Ma J. Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: an open-label, noninferiority, multicenter, randomized phase 3 trial. CA Cancer J Clin. 2025;75:203\u201315.","journal-title":"CA Cancer J Clin"},{"key":"1943_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"key":"1943_CR6","doi-asserted-by":"crossref","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A. W.J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010;363:711\u2013723.","DOI":"10.1056\/NEJMoa1003466"},{"key":"1943_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11:39.","journal-title":"J Hematol Oncol"},{"key":"1943_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","volume":"20","author":"AG Atanasov","year":"2021","unstructured":"Atanasov AG, Zotchev SB, Dirsch VM, International Natural T, Sciences P, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20:200\u201316.","journal-title":"Nat Rev Drug Discov"},{"key":"1943_CR9","doi-asserted-by":"publisher","first-page":"111011","DOI":"10.1016\/j.cellsig.2023.111011","volume":"115","author":"J Wu","year":"2024","unstructured":"Wu J, Ji H, Li T, Guo H, Xu H, Zhu J, Tian J, Gao M, Wang X, Zhang A. Targeting the prostate tumor microenvironment by plant-derived natural products. Cell Signal. 2024;115:111011.","journal-title":"Cell Signal"},{"key":"1943_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/DDDT.S278975","volume":"15","author":"J Yang","year":"2021","unstructured":"Yang J, Cao L, Li Y, Liu H, Zhang M, Ma H, Wang B, Yuan X, Liu Q. Gracillin isolated from Reineckia carnea induces apoptosis of A549 cells via the mitochondrial pathway. Drug Des Devel Ther. 2021;15:233\u201343.","journal-title":"Drug Des Devel Ther"},{"key":"1943_CR11","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3892\/mmr.2021.12199","volume":"24","author":"L Sha","year":"2021","unstructured":"Sha L, Lv Z, Liu Y, Zhang Y, Sui X, Wang T, Zhang H. Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer. Mol Med Rep. 2021;24:560.","journal-title":"Mol Med Rep"},{"key":"1943_CR12","doi-asserted-by":"crossref","unstructured":"Yadav S, Sharma A, Nayik GA, Cooper R, Bhardwaj G, Sohal HS, Mutreja V, Kaur R, Areche FO, AlOudat M, Shaikh AM, Kovacs B, Mohamed AE, A. Review of Shikonin and derivatives: isolation, chemistry, biosynthesis, Pharmacology and toxicology. Front Pharmacol. 2022;13:905755.","DOI":"10.3389\/fphar.2022.905755"},{"key":"1943_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.fitote.2019.03.005","volume":"134","author":"F Wang","year":"2019","unstructured":"Wang F, Yao X, Zhang Y, Tang J. Synthesis, biological function and evaluation of Shikonin in cancer therapy. Fitoterapia. 2019;134:329\u201339.","journal-title":"Fitoterapia"},{"key":"1943_CR14","doi-asserted-by":"publisher","first-page":"121077","DOI":"10.1016\/j.lfs.2022.121077","volume":"310","author":"Q Chen","year":"2022","unstructured":"Chen Q, Han H, Lin F, Yang L, Feng L, Lai X, Wen Z, Yang M, Wang C, Ma Y, Yin T, Lu G, Lin H, Qi J, Yang Y. Novel Shikonin derivatives suppress cell proliferation, migration and induce apoptosis in human triple-negative breast cancer cells via regulating PDK1\/PDHC axis. Life Sci. 2022;310:121077.","journal-title":"Life Sci"},{"key":"1943_CR15","doi-asserted-by":"publisher","first-page":"115138","DOI":"10.1016\/j.biopha.2023.115138","volume":"165","author":"Y Guo","year":"2023","unstructured":"Guo Y, Zhou M, Mu Z, Guo J, Hou Y, Xu Y, Geng L. Recent advances in Shikonin for the treatment of immune-related diseases: Anti-inflammatory and Immunomodulatory mechanisms. Biomed Pharmacother. 2023;165:115138.","journal-title":"Biomed Pharmacother"},{"key":"1943_CR16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/molecules21101278","volume":"21","author":"S Feng","year":"2016","unstructured":"Feng S, Reuss L, Wang Y. Potential of natural products in the Inhibition of adipogenesis through regulation of PPARgamma expression and\/or its transcriptional activity. Molecules. 2016;21:1278.","journal-title":"Molecules"},{"key":"1943_CR17","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/ijc.21943","volume":"119","author":"F Yang","year":"2006","unstructured":"Yang F, Chen Y, Duan W, Zhang C, Zhu H, Ding J. SH-7, a new synthesized Shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor. Int J Cancer. 2006;119:1184\u201393.","journal-title":"Int J Cancer"},{"key":"1943_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.12659\/MSM.908381","volume":"24","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Sun B, Huang Z, Zhao DW, Zeng Q. Shikonin inhibites migration and invasion of thyroid cancer cells by downregulating DNMT1. Med Sci Monit. 2018;24:661\u201370.","journal-title":"Med Sci Monit"},{"key":"1943_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16:71.","journal-title":"J Nanobiotechnol"},{"key":"1943_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"1943_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semcdb.2015.08.004","volume":"43","author":"WJ Israelsen","year":"2015","unstructured":"Israelsen WJ, Vander Heiden MG. Pyruvate kinase: function, regulation and role in cancer. Semin Cell Dev Biol. 2015;43:43\u201351.","journal-title":"Semin Cell Dev Biol"},{"key":"1943_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029\u201333.","journal-title":"Science"},{"key":"1943_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature06734","volume":"452","author":"HR Christofk","year":"2008","unstructured":"Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230\u20133.","journal-title":"Nature"},{"key":"1943_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1476-4598-12-152","volume":"12","author":"S Ganapathy-Kanniappan","year":"2013","unstructured":"Ganapathy-Kanniappan S, Geschwind JF. Tumor Glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152.","journal-title":"Mol Cancer"},{"key":"1943_CR25","doi-asserted-by":"publisher","first-page":"8363","DOI":"10.3390\/ijms21218363","volume":"21","author":"JX Wang","year":"2020","unstructured":"Wang JX, Choi SYC, Niu X, Kang N, Xue H, Killam J, Wang Y. Lactic acid and an acidic tumor microenvironment suppress anticancer immunity. Int J Mol Sci. 2020;21:8363.","journal-title":"Int J Mol Sci"},{"key":"1943_CR26","doi-asserted-by":"publisher","first-page":"112471","DOI":"10.1016\/j.celrep.2023.112471","volume":"42","author":"B Dang","year":"2023","unstructured":"Dang B, Gao Q, Zhang L, Zhang J, Cai H, Zhu Y, Zhong Q, Liu J, Niu Y, Mao K, Xiao N, Liu WH, Lin SH, Huang J, Huang SC, Ho PC, Cheng SC. The glycolysis\/HIF-1alpha axis defines the inflammatory role of IL-4-primed macrophages. Cell Rep. 2023;42:112471.","journal-title":"Cell Rep"},{"key":"1943_CR27","doi-asserted-by":"publisher","first-page":"e1014774","DOI":"10.1080\/2162402X.2015.1014774","volume":"5","author":"OR Colegio","year":"2016","unstructured":"Colegio OR. Lactic acid polarizes macrophages to a tumor-promoting state. Oncoimmunology. 2016;5:e1014774.","journal-title":"Oncoimmunology"},{"key":"1943_CR28","doi-asserted-by":"publisher","first-page":"926945","DOI":"10.3389\/fphar.2022.926945","volume":"13","author":"B Huang","year":"2022","unstructured":"Huang B, Wang Q, Jiang L, Lu S, Li C, Xu C, Wang C, Zhang E, Zhang X. Shikonin ameliorated mice colitis by inhibiting dimerization and tetramerization of PKM2 in macrophages. Front Pharmacol. 2022;13:926945.","journal-title":"Front Pharmacol"},{"key":"1943_CR29","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","volume":"145","author":"W Luo","year":"2011","unstructured":"Luo W, Hu H, Chang R, Zhong J, Knabel M, O\u2019Meally R, Cole RN, Pandey A, Semenza GL. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011;145:732\u201344.","journal-title":"Cell"},{"key":"1943_CR30","doi-asserted-by":"publisher","first-page":"14517","DOI":"10.1038\/s41598-018-31615-y","volume":"8","author":"X Zhao","year":"2018","unstructured":"Zhao X, Zhu Y, Hu J, Jiang L, Li L, Jia S, Zen K. Shikonin inhibits tumor growth in mice by suppressing pyruvate kinase M2-mediated aerobic Glycolysis. Sci Rep. 2018;8:14517.","journal-title":"Sci Rep"},{"key":"1943_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"1943_CR32","doi-asserted-by":"publisher","first-page":"33159","DOI":"10.18632\/oncotarget.16565","volume":"8","author":"AS Syed Khaja","year":"2017","unstructured":"Syed Khaja AS, Toor SM, Salhat HE, Faour I, Ul Haq N, Ali BR, Elkord E. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget. 2017;8:33159\u201371.","journal-title":"Oncotarget"},{"key":"1943_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/imr.12148","volume":"258","author":"A Huynh","year":"2014","unstructured":"Huynh A, Zhang R, Turka LA. Signals and pathways controlling regulatory T cells. Immunol Rev. 2014;258:117\u201331.","journal-title":"Immunol Rev"},{"key":"1943_CR34","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1038\/s41598-018-21570-z","volume":"8","author":"F Ni","year":"2018","unstructured":"Ni F, Huang X, Chen Z, Qian W, Tong X. Shikonin exerts antitumor activity in burkitt\u2019s lymphoma by inhibiting C-MYC and PI3K\/AKT\/mTOR pathway and acts synergistically with doxorubicin. Sci Rep. 2018;8:3317.","journal-title":"Sci Rep"},{"key":"1943_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6:362.","journal-title":"Signal Transduct Target Ther"},{"key":"1943_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmet.2018.04.022","volume":"28","author":"W Li","year":"2018","unstructured":"Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, Wei S, Zhao L, Vatan L, Wen B, Shu P, Sun D, Kleer C, Wicha M, Sabel M, Tao K, Wang G, Zou W. Aerobic Glycolysis controls Myeloid-Derived suppressor cells and tumor immunity via a specific CEBPB isoform in Triple-Negative breast cancer. Cell Metab. 2018;28:87\u2013103. e6.","journal-title":"Cell Metab"},{"key":"1943_CR37","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","volume":"107","author":"E Gottfried","year":"2006","unstructured":"Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, Mackensen A, Kreutz M. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006;107:2013\u201321.","journal-title":"Blood"},{"key":"1943_CR38","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, Kastenberger M, Bogdan C, Schleicher U, Mackensen A, Ullrich E, Fichtner-Feigl S, Kesselring R, Mack M, Ritter U, Schmid M, Blank C, Dettmer K, Oefner PJ, Hoffmann P, Walenta S, Geissler EK, Pouyssegur J, Villunger A, Steven A, Seliger B, Schreml S, Haferkamp S, Kohl E, Karrer S, Berneburg M, Herr W, Mueller-Klieser W, Renner K, Kreutz M. LDHA-Associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24:657\u201371.","journal-title":"Cell Metab"},{"key":"1943_CR39","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12943-015-0435-9","volume":"14","author":"TJ Lin","year":"2015","unstructured":"Lin TJ, Lin HT, Chang WT, Mitapalli SP, Hsiao PW, Yin SY, Yang NS. Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components. Mol Cancer. 2015;14:174.","journal-title":"Mol Cancer"},{"key":"1943_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12929-015-0127-1","volume":"22","author":"RK Gara","year":"2015","unstructured":"Gara RK, Srivastava VK, Duggal S, Bagga JK, Bhatt M, Sanyal S, Mishra DP. Shikonin selectively induces apoptosis in human prostate cancer cells through the Endoplasmic reticulum stress and mitochondrial apoptotic pathway. J Biomed Sci. 2015;22:26.","journal-title":"J Biomed Sci"},{"key":"1943_CR41","doi-asserted-by":"publisher","first-page":"113059","DOI":"10.1016\/j.jep.2020.113059","volume":"263","author":"X Ma","year":"2020","unstructured":"Ma X, Yu M, Hao C, Yang W. Shikonin induces tumor apoptosis in glioma cells via Endoplasmic reticulum stress, and bax\/bak mediated mitochondrial outer membrane permeability. J Ethnopharmacol. 2020;263:113059.","journal-title":"J Ethnopharmacol"},{"key":"1943_CR42","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1021\/jf0495993","volume":"52","author":"PC Hsu","year":"2004","unstructured":"Hsu PC, Huang YT, Tsai ML, Wang YJ, Lin JK, Pan MH. Induction of apoptosis by Shikonin through coordinative modulation of the Bcl-2 family, p27, and p53, release of cytochrome c, and sequential activation of caspases in human colorectal carcinoma cells. J Agric Food Chem. 2004;52:6330\u20137.","journal-title":"J Agric Food Chem"},{"key":"1943_CR43","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3892\/ol.2022.13424","volume":"24","author":"Z Xu","year":"2022","unstructured":"Xu Z, Huang L, Zhang T, Liu Y, Fang F, Wu X, Chen W, Lan L, Zhang Y, Li N, Hu P. Shikonin inhibits the proliferation of cervical cancer cells via FAK\/AKT\/GSK3beta signalling. Oncol Lett. 2022;24:304.","journal-title":"Oncol Lett"},{"key":"1943_CR44","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.intimp.2014.01.027","volume":"19","author":"Y Xu","year":"2014","unstructured":"Xu Y, Xu X, Gao X, Chen H, Geng L. Shikonin suppresses IL-17-induced VEGF expression via blockage of JAK2\/STAT3 pathway. Int Immunopharmacol. 2014;19:327\u201333.","journal-title":"Int Immunopharmacol"},{"key":"1943_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jep.2018.01.026","volume":"216","author":"CS Huang","year":"2018","unstructured":"Huang CS, Chen HW, Lin TY, Lin AH, Lii CK. Shikonin upregulates the expression of drug-metabolizing enzymes and drug transporters in primary rat hepatocytes. J Ethnopharmacol. 2018;216:18\u201325.","journal-title":"J Ethnopharmacol"},{"key":"1943_CR46","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2131\/jts.43.513","volume":"43","author":"K Yamashita","year":"2018","unstructured":"Yamashita K, Miyazaki H, Shinoda S, Hagiwara S, Takahashi H, Itagaki H. Assessment of the skin sensitizing potential of chemicals, contained in foods and\/or cosmetic ingredients, using a modified local lymph node assay with an elicitation phase (LLNA:DAE) method. J Toxicol Sci. 2018;43:513\u201320.","journal-title":"J Toxicol Sci"},{"key":"1943_CR47","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3390\/toxins6051559","volume":"6","author":"A Lupescu","year":"2014","unstructured":"Lupescu A, Bissinger R, Jilani K, Lang F. Vitro induction of erythrocyte phosphatidylserine translocation by the natural naphthoquinone Shikonin. Toxins (Basel). 2014;6:1559\u201374.","journal-title":"Toxins (Basel)"},{"key":"1943_CR48","doi-asserted-by":"publisher","first-page":"153805","DOI":"10.1016\/j.phymed.2021.153805","volume":"94","author":"Q Sun","year":"2022","unstructured":"Sun Q, Gong T, Liu M, Ren S, Yang H, Zeng S, Zhao H, Chen L, Ming T, Meng X, Xu H. Shikonin, a naphthalene ingredient: therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches. Phytomedicine. 2022;94:153805.","journal-title":"Phytomedicine"},{"key":"1943_CR49","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/IJN.S401570","volume":"18","author":"C Yan","year":"2023","unstructured":"Yan C, Li Q, Sun Q, Yang L, Liu X, Zhao Y, Shi M, Li X, Luo K. Promising nanomedicines of Shikonin for cancer therapy. Int J Nanomed. 2023;18:1195\u2013218.","journal-title":"Int J Nanomed"},{"key":"1943_CR50","doi-asserted-by":"publisher","first-page":"e00020","DOI":"10.1042\/BSR20120065","volume":"33","author":"H Xia","year":"2013","unstructured":"Xia H, Tang C, Gui H, Wang X, Qi J, Wang X, Yang Y. Preparation, cellular uptake and angiogenic suppression of shikonin-containing liposomes in vitro and in vivo. Biosci Rep. 2013;33:e00020.","journal-title":"Biosci Rep"},{"key":"1943_CR51","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1163\/092050611X605933","volume":"23","author":"A Ishihara","year":"2012","unstructured":"Ishihara A, Yamauchi M, Tsuchiya T, Mimura Y, Tomoda Y, Katagiri A, Kamiya M, Nemoto H, Suzawa T, Yamasaki M. A novel liposome surface modification agent that prolongs blood circulation and retains surface ligand reactivity. J Biomater Sci Polym Ed. 2012;23:2055\u201368.","journal-title":"J Biomater Sci Polym Ed"},{"key":"1943_CR52","doi-asserted-by":"crossref","unstructured":"Wen X, Li J, Cai D, Yue L, Wang Q, Zhou L, Fan L, Sun J, Wu Y. Anticancer efficacy of targeted shikonin liposomes modified with RGD in breast cancer cells. Molecules, 2018;23:268.","DOI":"10.3390\/molecules23020268"},{"key":"1943_CR53","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jconrel.2023.12.052","volume":"366","author":"J Zhu","year":"2024","unstructured":"Zhu J, Wang R, Yang C, Shao X, Zhang Y, Hou J, Gao Y, Ou A, Chen M, Huang Y. Blocking tumor-platelet crosstalk to prevent tumor metastasis via reprograming Glycolysis using biomimetic membrane-hybridized liposomes. J Control Release. 2024;366:328\u201341.","journal-title":"J Control Release"},{"key":"1943_CR54","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ijpharm.2011.09.031","volume":"422","author":"KN Kontogiannopoulos","year":"2012","unstructured":"Kontogiannopoulos KN, Assimopoulou AN, Hatziantoniou S, Karatasos K, Demetzos C, Papageorgiou VP. Chimeric advanced drug delivery nano systems (chi-aDDnSs) for Shikonin combining dendritic and liposomal technology. Int J Pharm. 2012;422:381\u20139.","journal-title":"Int J Pharm"},{"key":"1943_CR55","doi-asserted-by":"publisher","first-page":"113096","DOI":"10.1016\/j.colsurfb.2022.113096","volume":"222","author":"X Wang","year":"2023","unstructured":"Wang X, Guo W, Han J, Li J, Zhao Q, Mao Y, Wang S. Oral spatial-to-point cascade targeting sugar-coated bullets for precise and safe chemotherapy by intervention Warburg effect. Colloids Surf B Biointerfaces. 2023;222:113096.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1943_CR56","first-page":"1855","volume":"9","author":"EI Matthaiou","year":"2014","unstructured":"Matthaiou EI, Barar J, Sandaltzopoulos R, Li C, Coukos G, Omidi Y. Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. Int J Nanomed. 2014;9:1855\u201370.","journal-title":"Int J Nanomed"},{"key":"1943_CR57","doi-asserted-by":"publisher","first-page":"50734","DOI":"10.1021\/acsami.0c14909","volume":"12","author":"J Li","year":"2020","unstructured":"Li J, Zhao M, Sun M, Wu S, Zhang H, Dai Y, Wang D. Multifunctional nanoparticles boost cancer immunotherapy based on modulating the immunosuppressive tumor microenvironment. ACS Appl Mater Interfaces. 2020;12:50734\u201347.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1943_CR58","doi-asserted-by":"publisher","first-page":"101448","DOI":"10.1016\/j.nantod.2022.101448","volume":"44","author":"P Zhao","year":"2022","unstructured":"Zhao P, Qu J, Wu A, Wang S, Tang X, Ou A, Zhang J, Xu Y, Zhao Q, Huang Y. Anti-alcoholism drug Disulfiram for targeting glioma energy metabolism using BBB-penetrating delivery of fixed-dose combination. Nano Today. 2022;44:101448.","journal-title":"Nano Today"},{"key":"1943_CR59","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1021\/acs.nanolett.9b00021","volume":"19","author":"H Wang","year":"2019","unstructured":"Wang H, Tang Y, Fang Y, Zhang M, Wang H, He Z, Wang B, Xu Q, Huang Y. Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of Shikonin\/JQ1. Nano Lett. 2019;19:2935\u201344.","journal-title":"Nano Lett"},{"key":"1943_CR60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/jlcr.3818","volume":"63","author":"H Fayez","year":"2020","unstructured":"Fayez H, El-Motaleb MA, Selim AA. Synergistic cytotoxicity of Shikonin-Silver nanoparticles as an opportunity for lung cancer. J Label Comp Radiopharm. 2020;63:25\u201332.","journal-title":"J Label Comp Radiopharm"},{"key":"1943_CR61","doi-asserted-by":"publisher","first-page":"100245","DOI":"10.1016\/j.mtadv.2022.100245","volume":"14","author":"J Liang","year":"2022","unstructured":"Liang J, Wang C, Fan J, Xie Q, Yu Z, Liu B, Tian Y, Ning J, Feng L, Wang W. Hybrid membrane-camouflaged Hollow Prussian blue nanoparticles for Shikonin loading and combined chemo\/photothermal therapy of metastatic TNBC. Mater Today Adv. 2022;14:100245.","journal-title":"Mater Today Adv"},{"key":"1943_CR62","doi-asserted-by":"publisher","first-page":"e2200742","DOI":"10.1002\/adhm.202200742","volume":"11","author":"J Peng","year":"2022","unstructured":"Peng J, Hu X, Fan S, Zhou J, Ren S, Sun R, Chen Y, Shen X, Chen Y. Inhibition of mitochondrial biosynthesis using a Right-Side-Out Membrane-Camouflaged micelle to facilitate the therapeutic effects of Shikonin on Triple-Negative breast cancer. Adv Healthc Mater. 2022;11:e2200742.","journal-title":"Adv Healthc Mater"},{"key":"1943_CR63","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.2147\/IJN.S132639","volume":"12","author":"Y Su","year":"2017","unstructured":"Su Y, Huang N, Chen D, Zhang L, Dong X, Sun Y, Zhu X, Zhang F, Gao J, Wang Y, Fan K, Lo P, Li W, Ling C. Successful in vivo hyperthermal therapy toward breast cancer by Chinese medicine shikonin-loaded thermosensitive micelle. Int J Nanomed. 2017;12:4019\u201335.","journal-title":"Int J Nanomed"},{"key":"1943_CR64","doi-asserted-by":"crossref","unstructured":"Li S, Zhang T, Xu W, Ding J, Yin F, Xu J, Sun W, Wang H, Sun M, Cai Z, Hua Y. Sarcoma-targeting peptide-decorated polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis. Theranostics, 2018;8:1361\u20131375.","DOI":"10.7150\/thno.18299"},{"key":"1943_CR65","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1016\/j.xphs.2021.03.018","volume":"110","author":"H Wang","year":"2021","unstructured":"Wang H, Chen W, Wu G, Kong J, Yuan S, Chen L. A magnetic T7 Peptide&AS1411 Aptamer-Modified microemulsion for triple Glioma-Targeted delivery of Shikonin and docetaxel. J Pharm Sci. 2021;110:2946\u201354.","journal-title":"J Pharm Sci"},{"key":"1943_CR66","doi-asserted-by":"crossref","unstructured":"Xing H, Hwang K, Lu Y. Recent developments of liposomes as nanocarriers for theranostic applications. Theranostics 2016;6:1336\u201352.","DOI":"10.7150\/thno.15464"},{"key":"1943_CR67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0378-5173(00)00635-9","volume":"214","author":"G Purohit","year":"2001","unstructured":"Purohit G, Sakthivel T, Florence AT. Interaction of cationic partial dendrimers with charged and neutral liposomes. Int J Pharm. 2001;214:71\u20136.","journal-title":"Int J Pharm"},{"key":"1943_CR68","doi-asserted-by":"publisher","first-page":"11639","DOI":"10.1158\/0008-5472.CAN-05-1190","volume":"65","author":"V Carriere","year":"2005","unstructured":"Carriere V, Colisson R, Jiguet-Jiglaire C, Bellard E, Bouche G, Al Saati T, Amalric F, Girard JP. M\u2019Rini, cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node. Cancer Res. 2005;65:11639\u201348.","journal-title":"Cancer Res"},{"key":"1943_CR69","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/imt-2016-0135","volume":"9","author":"AJ Petty","year":"2017","unstructured":"Petty AJ, Yang Y. Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy. 2017;9:289\u2013302.","journal-title":"Immunotherapy"},{"key":"1943_CR70","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nri3902","volume":"15","author":"SJ Turley","year":"2015","unstructured":"Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15:669\u201382.","journal-title":"Nat Rev Immunol"},{"key":"1943_CR71","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fimmu.2016.00052","volume":"7","author":"S Romero-Garcia","year":"2016","unstructured":"Romero-Garcia S, Moreno-Altamirano MM, Prado-Garcia H, Sanchez-Garcia FJ. Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. Front Immunol. 2016;7:52.","journal-title":"Front Immunol"},{"key":"1943_CR72","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3389\/fimmu.2017.01360","volume":"8","author":"AL Mellor","year":"2017","unstructured":"Mellor AL, Lemos H, Huang L. Indoleamine 2,3-Dioxygenase and tolerance: where are we now?? Front Immunol. 2017;8:1360.","journal-title":"Front Immunol"},{"key":"1943_CR73","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","volume":"115","author":"X Liu","year":"2010","unstructured":"Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA. Selective Inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115:3520\u201330.","journal-title":"Blood"},{"key":"1943_CR74","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T. Van Den eynde, evidence for a tumoral immune resistance mechanism based on Tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269\u201374.","journal-title":"Nat Med"},{"key":"1943_CR75","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.celrep.2015.08.077","volume":"13","author":"RB Holmgaard","year":"2015","unstructured":"Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-Expressed IDO recruits and activates MDSCs in a Treg-Dependent manner. Cell Rep. 2015;13:412\u201324.","journal-title":"Cell Rep"},{"key":"1943_CR76","doi-asserted-by":"publisher","first-page":"120310","DOI":"10.1016\/j.ijpharm.2021.120310","volume":"597","author":"J Li","year":"2021","unstructured":"Li J, Zhao M, Xu Y, Hu X, Dai Y, Wang D. Hybrid micelles codelivering Shikonin and IDO-1 SiRNA enhance immunotherapy by remodeling immunosuppressive tumor microenvironment. Int J Pharm. 2021;597:120310.","journal-title":"Int J Pharm"},{"key":"1943_CR77","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519\u201330.","journal-title":"J Gen Physiol"},{"key":"1943_CR78","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/ncb3630","volume":"19","author":"F Liu","year":"2017","unstructured":"Liu F, Ma F, Wang Y, Hao L, Zeng H, Jia C, Wang Y, Liu P, Ong IM, Li B, Chen G, Jiang J, Gong S, Li L, Xu W. PKM2 methylation by CARM1 activates aerobic Glycolysis to promote tumorigenesis. Nat Cell Biol. 2017;19:1358\u201370.","journal-title":"Nat Cell Biol"},{"key":"1943_CR79","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and damps in cancer therapy. Nat Rev Cancer. 2012;12:860\u201375.","journal-title":"Nat Rev Cancer"},{"key":"1943_CR80","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1164\/rccm.201201-0084OC","volume":"186","author":"RM Kottmann","year":"2012","unstructured":"Kottmann RM, Kulkarni AA, Smolnycki KA, Lyda E, Dahanayake T, Salibi R, Honnons S, Jones C, Isern NG, Hu JZ, Nathan SD, Grant G, Phipps RP, Sime PJ. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-beta. Am J Respir Crit Care Med. 2012;186:740\u201351.","journal-title":"Am J Respir Crit Care Med"},{"key":"1943_CR81","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1535-6108(03)00304-0","volume":"4","author":"Z Lu","year":"2003","unstructured":"Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 2003;4:499\u2013515.","journal-title":"Cancer Cell"},{"key":"1943_CR82","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13046-023-02688-z","volume":"42","author":"L Long","year":"2023","unstructured":"Long L, Xiong W, Lin F, Hou J, Chen G, Peng T, He Y, Wang R, Xu Q, Huang Y. Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using Shikonin targeted delivery. J Exp Clin Cancer Res. 2023;42:117.","journal-title":"J Exp Clin Cancer Res"},{"key":"1943_CR83","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jamaoncol.2017.4996","volume":"4","author":"RD Issels","year":"2018","unstructured":"Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P, Ghadjar P, Hohenberger P, Angele M, Salat C, Vujaskovic Z, Daugaard S, Mella O, Mansmann U, Durr HR, Knosel T, Abdel-Rahman S, Schmidt M, Hiddemann W, Jauch KW, Belka C, Gronchi A. European organization for the, T. Treatment of Cancer-Soft, G. Bone sarcoma, O. the European society for hyperthermic, effect of neoadjuvant chemotherapy plus regional hyperthermia on Long-term outcomes among patients with localized High-Risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncol. 2018;4:483\u201392.","journal-title":"JAMA Oncol"},{"key":"1943_CR84","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.semradonc.2022.10.011","volume":"33","author":"OJ Ott","year":"2023","unstructured":"Ott OJ, Gaipl US, Lamrani A, Fietkau R. The emerging evidence supporting integration of deep regional hyperthermia with chemoradiation in bladder cancer. Semin Radiat Oncol. 2023;33:82\u201390.","journal-title":"Semin Radiat Oncol"},{"key":"1943_CR85","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1038\/s41388-018-0169-4","volume":"37","author":"T Su","year":"2018","unstructured":"Su T, Liao J, Dai Z, Xu L, Chen S, Wang Y, Peng Z, Zhang Q, Peng S, Kuang M. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. Oncogene. 2018;37:3514\u201327.","journal-title":"Oncogene"},{"key":"1943_CR86","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2021.06.001","volume":"518","author":"Y Chen","year":"2021","unstructured":"Chen Y, Bei J, Liu M, Huang J, Xie L, Huang W, Cai M, Guo Y, Lin L, Zhu K. Sublethal heat stress-induced O-GlcNAcylation coordinates the Warburg effect to promote hepatocellular carcinoma recurrence and metastasis after thermal ablation. Cancer Lett. 2021;518:23\u201334.","journal-title":"Cancer Lett"},{"key":"1943_CR87","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00330-014-3483-4","volume":"25","author":"J Yu","year":"2015","unstructured":"Yu J, Liang P, Yu XL, Cheng ZG, Han ZY, Mu MJ, Li QY, Liu YM. Local tumour progression after ultrasound-guided microwave ablation of liver malignancies: risk factors analysis of 2529 tumours. Eur Radiol. 2015;25:1119\u201326.","journal-title":"Eur Radiol"},{"key":"1943_CR88","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.yexcr.2017.03.046","volume":"354","author":"MI Mitov","year":"2017","unstructured":"Mitov MI, Harris JW, Alstott MC, Zaytseva YY, Evers BM, Butterfield DA. Temperature induces significant changes in both glycolytic reserve and mitochondrial spare respiratory capacity in colorectal cancer cell lines. Exp Cell Res. 2017;354:112\u201321.","journal-title":"Exp Cell Res"},{"key":"1943_CR89","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1021\/acsbiomaterials.3c00644","volume":"9","author":"L Chen","year":"2023","unstructured":"Chen L, Zhao D, Ren X, Ren J, Meng X, Fu C, Li X. Shikonin-Loaded Hollow Fe-MOF nanoparticles for enhanced microwave thermal therapy. ACS Biomater Sci Eng. 2023;9:5405\u201317.","journal-title":"ACS Biomater Sci Eng"},{"key":"1943_CR90","doi-asserted-by":"publisher","first-page":"e2101926","DOI":"10.1002\/adhm.202101926","volume":"11","author":"W Feng","year":"2022","unstructured":"Feng W, Shi W, Liu S, Liu H, Liu Y, Ge P, Zhang H. Fe(III)-Shikonin supramolecular nanomedicine for combined therapy of tumor via ferroptosis and necroptosis. Adv Healthc Mater. 2022;11:e2101926.","journal-title":"Adv Healthc Mater"},{"key":"1943_CR91","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12951-023-01771-z","volume":"21","author":"F Shen","year":"2023","unstructured":"Shen F, Fang Y, Wu Y, Zhou M, Shen J, Fan X. Metal ions and nanometallic materials in antitumor immunity: function, application, and perspective. J Nanobiotechnol. 2023;21:20.","journal-title":"J Nanobiotechnol"},{"key":"1943_CR92","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1021\/acsnano.4c12195","volume":"19","author":"Z Lu","year":"2025","unstructured":"Lu Z, Fan W, Ye Y, Huang Y, Zhou X, Zhang Y, Cui W, Ji J, Yao K, Han H. Drug in drug: quorum sensing inhibitor in Star-Shaped antibacterial polypeptides for inhibiting and eradicating corneal bacterial biofilms. ACS Nano. 2025;19:2268\u201385.","journal-title":"ACS Nano"},{"key":"1943_CR93","doi-asserted-by":"publisher","first-page":"14475","DOI":"10.1021\/acsnano.3c00901","volume":"17","author":"W Shi","year":"2023","unstructured":"Shi W, Feng W, Li S, Cui Y, Liu S, Jiang H, Liu Y, Zhang H. Ferroptosis and necroptosis produced autologous tumor cell lysates Co-Delivering with combined immnoadjuvants as personalized in situ nanovaccines for antitumor immunity. ACS Nano. 2023;17:14475\u201393.","journal-title":"ACS Nano"},{"key":"1943_CR94","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2021.05.040","volume":"335","author":"J Li","year":"2021","unstructured":"Li J, Zhou S, Yu J, Cai W, Yang Y, Kuang X, Liu H, He Z, Wang Y. Low dose Shikonin and anthracyclines coloaded liposomes induce robust Immunogenetic cell death for synergistic chemo-immunotherapy. J Control Release. 2021;335:306\u201319.","journal-title":"J Control Release"},{"key":"1943_CR95","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","volume":"240","author":"YN Zhang","year":"2016","unstructured":"Zhang YN, Poon W, Tavares AJ, McGilvray ID, Chan WCW. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332\u201348.","journal-title":"J Control Release"},{"key":"1943_CR96","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","volume":"154\u2013155","author":"GT Kozma","year":"2020","unstructured":"Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to pegylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154\u2013155:163\u201375.","journal-title":"Adv Drug Deliv Rev"},{"key":"1943_CR97","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1208\/s12248-021-00630-9","volume":"23","author":"Z Wang","year":"2021","unstructured":"Wang Z, Brenner JS. The Nano-War against complement proteins. AAPS J. 2021;23:105.","journal-title":"AAPS J"},{"key":"1943_CR98","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","volume":"61","author":"J Szebeni","year":"2014","unstructured":"Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol. 2014;61:163\u201373.","journal-title":"Mol Immunol"},{"key":"1943_CR99","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/nano13071171","volume":"13","author":"C Yang","year":"2023","unstructured":"Yang C, Merlin D. Challenges to safe nanomedicine treatment. Nanomaterials (Basel). 2023;13:1171.","journal-title":"Nanomaterials (Basel)"},{"key":"1943_CR100","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.tibtech.2008.04.005","volume":"26","author":"N Sanvicens","year":"2008","unstructured":"Sanvicens N, Marco MP. Multifunctional nanoparticles\u2013properties and prospects for their use in human medicine. Trends Biotechnol. 2008;26:425\u201333.","journal-title":"Trends Biotechnol"},{"key":"1943_CR101","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.4103\/0366-6999.235105","volume":"131","author":"JP Chen","year":"2018","unstructured":"Chen JP, Shi SS, Liu GF, Chen Y, Zheng SS, Wang XB, Lin RH, He HX, Lin CH. Potential clinical risk of inflammation and toxicity from Rare-Earth nanoparticles in mice. Chin Med J (Engl). 2018;131:1591\u20137.","journal-title":"Chin Med J (Engl)"},{"key":"1943_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-bioeng-071811-150124","volume":"14","author":"A Albanese","year":"2012","unstructured":"Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1\u201316.","journal-title":"Annu Rev Biomed Eng"},{"key":"1943_CR103","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/smll.200900626","volume":"6","author":"TS Hauck","year":"2010","unstructured":"Hauck TS, Anderson RE, Fischer HC, Newbigging S, Chan WC. Vivo quantum-dot toxicity assessment. Small. 2010;6:138\u201344.","journal-title":"Small"},{"key":"1943_CR104","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41427-022-00416-1","volume":"14","author":"X Chen","year":"2022","unstructured":"Chen X, Lv H. Intelligent control of nanoparticle synthesis on microfluidic chips with machine learning. NPG Asia Mater. 2022;14:69.","journal-title":"NPG Asia Mater"},{"key":"1943_CR105","doi-asserted-by":"publisher","first-page":"107199","DOI":"10.1016\/j.measurement.2019.107199","volume":"151","author":"GR Khayati","year":"2020","unstructured":"Khayati GR. A predictive model on size of silver nanoparticles prepared by green synthesis method using hybrid artificial neural network-particle swarm optimization algorithm. Measurement. 2020;151:107199.","journal-title":"Measurement"},{"key":"1943_CR106","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.pan.2021.01.023","volume":"21","author":"Z Ruan","year":"2021","unstructured":"Ruan Z, Liang M, Shang L, Lai M, Deng X, Su X. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-kappaB\/STAT3 and NF-kappaB\/CSN5 signaling pathways. Pancreatology. 2021;21:630\u201341.","journal-title":"Pancreatology"},{"key":"1943_CR107","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1111\/cas.14379","volume":"111","author":"S Saito","year":"2020","unstructured":"Saito S, Koya Y, Kajiyama H, Yamashita M, Kikkawa F, Nawa A. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter. Cancer Sci. 2020;111:1794\u2013804.","journal-title":"Cancer Sci"},{"key":"1943_CR108","doi-asserted-by":"crossref","unstructured":"Genoud V, Marinari E, Nikolaev SI, Castle JC, Bukur V, Dietrich PY, Okada H, Walker PR. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint Blockade in SB28 and GL261 mouse glioma models. Oncoimmunology. 2018;7:e1501137.","DOI":"10.1080\/2162402X.2018.1501137"},{"key":"1943_CR109","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1021\/acsnano.6b04268","volume":"10","author":"T Lin","year":"2016","unstructured":"Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, He H, Yang VC, Huang Y. Blood-Brain-Barrier-Penetrating albumin nanoparticles for biomimetic drug delivery via albumin-Binding protein pathways for antiglioma therapy. ACS Nano. 2016;10:9999\u201310012.","journal-title":"ACS Nano"},{"key":"1943_CR110","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.actbio.2022.08.072","volume":"152","author":"Z Huang","year":"2022","unstructured":"Huang Z, Ding Y, Luo Y, Chen M, Zeng Z, Zhang T, Sun Y, Huang Y, Zhao C. ROS-triggered cycle amplification effect: A prodrug activation nanoamplifier for tumor-specific therapy. Acta Biomater. 2022;152:367\u201379.","journal-title":"Acta Biomater"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01943-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01943-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01943-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T23:02:32Z","timestamp":1765148552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01943-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01943-4","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"28 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review article is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This review article is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}